New hope for tough cancers: targeted drug trial launches

NCT ID NCT06553885

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing enfortumab vedotin, a drug that delivers chemotherapy directly to cancer cells, in 40 adults with advanced colorectal or liver cancer that has worsened after standard treatments. The main goal is to see if the drug can shrink tumors. Researchers will also track how long any response lasts and how long patients live without their cancer growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enfortumab vedotin (an antibody-drug conjugate that targets cancer cells)
What this could lead to: If successful, this could provide a new treatment option for people with advanced colorectal or liver cancer who have not responded to standard therapies.
What could go wrong: This is an early phase 2 trial with only 40 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects like nerve damage or skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.